 







<USDEPT>DEPARTMENT OF HEALTH AND HUMAN SERVICES</USDEPT>



<USBUREAU>Food and Drug Administration</USBUREAU>


Advisory Committees; Notice of Meetings


<AGENCY>
AGENCY: 

Food and Drug Administration, HHS.


</AGENCY>
<ACTION>
ACTION: 

Notice.



</ACTION>
<SUMMARY>
SUMMARY: 

This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA).
This notice also summarizes the procedures for the meetings and methods by which interested persons may participate
in open public hearings before FDA's advisory committees.

 

MEETINGS: 

The following advisory committee meetings are announced:


Antiviral Drugs Advisory Committee



Date, time, and place

. September 12 and 13, 1994, 8:30 a.m.; Holiday Inn, Plaza Ballroom, 8777 Georgia Ave., Silver Spring, MD.


Type of meeting and contact person

. Open committee discussion, September 12, 1994, 8:30 a.m. to 11:30 a.m.; open public hearing, 11:30 a.m. to 12 m.,
unless public participation does not last that long; open committee discussion, 12 m. to 5 p.m.; open committee discussion,
September 13, 1994, 8:30 a.m. to 11:30 a.m.; open public hearing, 11:30 a.m. to 12 m., unless public participation
does not last that long; open committee discussion, 12 m. to 4 p.m.; Lee L. Zwanziger or Valerie Mealy, Center for Drug
Evaluation and Research (HFD9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 3014434695.


General function of the committee

. The committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational
human drug products for use in the treatment of acquired immune deficiency syndrome (AIDS), AIDS-related complex
(ARC), and other viral, fungal, and mycobacterial infections.


Agenda_Open public hearing

. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.
Those desiring to make formal presentations should notify the contact person before September 2, 1994, and submit
a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of
proposed participants, and an indication of the approximate time required to make their comments.


Open committee discussion

. The committee will discuss scientific and medical issues relevant to the validation of surrogate markers for use
as criteria in regulatory decisionmaking.


Anti-Infective Drugs Advisory Committee



Date, time, and place

. September 23, 1994, 8 a.m., 
Holiday Inn, Plaza Ballroom, 8777 Georgia Ave., Silver Spring, MD.


Type of meeting and contact person

. Open public hearing, 8 a.m. to 9 a.m., unless public participation does not last that long; open committee discussion,
9 a.m. to 11:30 a.m.; Ermona B. McGoodwin or Mary Elizabeth Donahue, Center for Drug Evaluation and Research (HFD9),
Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 3014435455. 


General function of the committee

. The Anti-Infective Drugs Advisory Committee reviews and evaluates data relating to the safety and effectiveness
of marketed and investigational human drugs for use in infectious and ophthalmic disorders. 


Agenda_Open public hearing

. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.
Those desiring to make formal presentations should notify the contact person before September 16, 1994, and submit
a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of
proposed participants, and an indication of the approximate time required to make their comments.


Open committee discussion

. The committee will discuss surrogate markers, such as pharmacokinetic parameters and microbiological inhibitory
and cidal data, and whether these parameters can be used instead of clinical efficacy data to support an alternative
dosing regimen for oral metronidazole in the treatment of Trichomonas vaginalis vaginitis.


Joint Meeting of the Dermatologic Drugs and Anti-Infective Drugs Advisory Committees



Date, time, and place

. September 23, 1994, 1 p.m., 
conference rms. D and E , Parklawn Bldg., 5600 Fishers Lane, Rockville, MD. 


Type of meeting and contact person

. Open public hearing, 1 p.m. to 2 p.m., unless public participation does not last that long; open committee discussion,
2 p.m. to 5 p.m.; Ermona B. McGoodwin or Valerie Mealy, Center for Drug Evaluation and Research (HFD9), Food
and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 3014435455. 


General function of the committees

. The Dermatologic Drugs Advisory Committee reviews and evaluates data on the safety and effectiveness of marketed
and investigational human drugs for use in the treatment of dermatologic diseases. The Anti-Infective Drugs Advisory
Committee reviews and evaluates data relating to the safety and effectiveness of marketed and investigational human
drugs for use in infectious and ophthalmic disorders. 


Agenda_Open public hearing

. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.
Those desiring to make formal presentations should notify the contact person before September 16, 1994, and submit
a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of
proposed participants, and an indication of the approximate time required to make their comments.


Open committee discussion

. The committees will discuss the potential for development of antibiotic resistance with over-the-counter use
of topical erythromycin in the treatment of acne. 


Peripheral and Central Nervous System Drugs Advisory Committee



Date, time, and place

. September 26 and 27, 1994, 8:30 a.m., conference rms. D and E, Parklawn Bldg., 5600 Fishers Lane, Rockville, MD.


Type of meeting and contact person

. Open public hearing, September 26, 1994, 8:30 a.m. to 9:30 a.m., unless public participation does not last that long;
open committee discussion, 9:30 a.m. to 5 p.m.; open public hearing, September 27, 1994, 8:30 a.m. to 9:30 a.m., unless
public participation does not last that long; open committee discussion, 9:30 a.m. to 5 p.m.; Michael A. Bernstein,
Center for Drug Evaluation and Research (HFD120), Food and Drug Administration, 5600 Fishers Lane, Rockville,
MD 20857, 3015942775.


General function of the committee

. The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human
drugs for use in neurological diseases.


Agenda_Open public hearing

. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.
Those desiring to make formal presentations should notify the contact person before September 19, 1994, and submit
a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of
proposed participants, and an indication of the approximate time required to make their comments.


Open committee discussions

. On September 26, 1994, the committee will discuss the safety and effectiveness of Freedox

&reg;

 (tirilazad mesylate), new drug application (NDA) 20399, The Upjohn Co., for use in the treatment of subarachnoid
hemorrhage. On September 27, 1994, the committee will discuss the safety and effectiveness of Tegretol

&reg;

 (carbamazepine), NDA 18927, Basel Pharmaceuticals, for use as an anticonvulsant in children under 6 years
old. Additionally, the committee will reconsider the relative risks and benefits of Felbatol

&reg;

 (felbamate), NDA 20189, Carter-Wallace, for use in the treatment of epilepsy.


National Mammography Quality Assurance Advisory Committee



Date, time, and place

. September 28, 1994, 10 a.m., and 
September 29 and 30, 1994, 8:30 a.m., Gaithersburg Hilton Hotel, 620 Perry Pkwy., Gaithersburg, MD. A limited number
of overnight accommodations have been reserved at the Gaithersburg Hilton Hotel. Attendees requiring overnight
accommodations may contact the hotel at 3019778900 and reference the FDA committee meeting block.
Reservations will be confirmed at the group rate based on availability.


Type of meeting and contact person

. Open public hearing, September 28, 1994, 10 a.m. to 11 a.m., unless public 
participation does not last that long; open committee discussion, 11 a.m. to 5 p.m.; open committee discussion, September
29, 1994, 8:30 a.m. to 5 p.m.; open committee discussion, September 30, 1994, 8:30 a.m. to 5 p.m.; Charles K. Showalter,
Center for Devices and Radiological Health (HFZ240), Food and Drug Administration, 1901 Chapman Ave., Rockville,
MD 20857, 3015943311.


General function of the committee

. The committee advises on developing appropriate quality standards and regulations for the use of mammography facilities.


Agenda_Open public hearing

. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.
Those desiring to make formal presentations should notify the contact person before September 23, 1994, and submit
a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of
proposed participants, and an indication of the approximate time required to make their comments.


Open committee discussion

. The committee will discuss the draft final standards for accreditation bodies and the draft 
final standards for facilities. Specific topics to be discussed include: States as certifying bodies, mobile units,
breast implant imaging, consumer complaint mechanism, and equipment other than the x-ray unit.
FDA public advisory committee meetings may have as many as four separable portions: (1) An open public hearing, (2)
an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory
committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three
portions will depend upon the specific meeting involved. There are no closed portions for the meetings announced
in this notice. The dates and times reserved for the open portions of each committee meeting are listed above.
The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last
that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather
than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee
chairperson determines will facilitate the committee's work.
Public hearings are subject to FDA's guideline (subpart C of 21 CFR part 10) concerning the policy and procedures for
electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory
committees under 21 CFR part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject
to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including
presentations by 
participants.
Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published
in this 

Federal Register

 notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.
Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion
of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person
attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make
an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion. 
The agenda, the questions to be addressed by the committee, and a current list of committee members will be available
at the meeting location on the day of the meeting.
Transcripts of the open portion of the meeting may be requested in writing from the Freedom of Information Office (HFI35),
Food and Drug Administration, rm. 12A16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working
days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch
(HFA305), Food and Drug Administration, rm. 123, 12420 Parklawn Dr., Rockville, MD 20857, approximately
15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of
the open portion of the meeting may be requested in writing from the Freedom of Information Office (address above)
beginning approximately 90 days after the meeting. 
This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's
regulations (21 CFR part 14) on advisory committees.





Dated: August 15, 1994.

</SUMMARY>
<SIGNER>
Linda A. Suydam,

</SIGNER>
<SIGNJOB>
Interim Deputy Commissioner for Operations.

</SIGNJOB>
<FRFILING>
[FR Doc. 9420510 Filed 81994; 8:45 am]

</FRFILING>
<BILLING>
BILLING CODE 416001F
</BILLING>


